Tags

Type your tag names separated by a space and hit enter

Meningococcal disease and travel.
Int J Antimicrob Agents. 2003 Feb; 21(2):102-6.IJ

Abstract

Meningococcal disease continues to be a worldwide problem. This review examines the impact meningococcal disease has on international travel and vice versa the impact international travel has on the intercontinental spread of meningococci. The risk of meningococcal disease to the endemic population differs from that of travellers. The best documented risk of meningococcal disease among travellers has been in Hajj pilgrims for Mecca and Madina in Saudi Arabia. In response to the recent Hajj associated outbreak of W135 meningococcal disease, quadrivalent meningococcal vaccine (against serogroups A/C/Y/W135) became a visa requirement. In view of increasing worldwide reports of Y and W135 meningococcal disease, there should be a switch in recommendation from the bivalent (against A& C) to the quadrivalent vaccine for all travellers.

Authors+Show Affiliations

Wilder-Smith A
Travellers' Health and Vaccination Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore. epvws@pacific.net.sg
Memish Z
No affiliation info available

MeSH

Disease OutbreaksHumansIslamMeningitis, MeningococcalMeningococcal InfectionsMeningococcal VaccinesNeisseria meningitidisRisk FactorsSaudi ArabiaTravel

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12615371

Citation

Wilder-Smith, Annelies, and Ziad Memish. "Meningococcal Disease and Travel." International Journal of Antimicrobial Agents, vol. 21, no. 2, 2003, pp. 102-6.
Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int J Antimicrob Agents. 2003;21(2):102-6.
Wilder-Smith, A., & Memish, Z. (2003). Meningococcal disease and travel. International Journal of Antimicrobial Agents, 21(2), 102-6.
Wilder-Smith A, Memish Z. Meningococcal Disease and Travel. Int J Antimicrob Agents. 2003;21(2):102-6. PubMed PMID: 12615371.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Meningococcal disease and travel. AU - Wilder-Smith,Annelies, AU - Memish,Ziad, PY - 2003/3/5/pubmed PY - 2003/12/4/medline PY - 2003/3/5/entrez SP - 102 EP - 6 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 21 IS - 2 N2 - Meningococcal disease continues to be a worldwide problem. This review examines the impact meningococcal disease has on international travel and vice versa the impact international travel has on the intercontinental spread of meningococci. The risk of meningococcal disease to the endemic population differs from that of travellers. The best documented risk of meningococcal disease among travellers has been in Hajj pilgrims for Mecca and Madina in Saudi Arabia. In response to the recent Hajj associated outbreak of W135 meningococcal disease, quadrivalent meningococcal vaccine (against serogroups A/C/Y/W135) became a visa requirement. In view of increasing worldwide reports of Y and W135 meningococcal disease, there should be a switch in recommendation from the bivalent (against A& C) to the quadrivalent vaccine for all travellers. SN - 0924-8579 UR - https://www.unboundmedicine.com/medline/citation/12615371/Meningococcal_disease_and_travel_ DB - PRIME DP - Unbound Medicine ER -